Synonyms: ZE46-0134
Compound class:
Synthetic organic
Comment: Lomonitinib is the INN for a tyrosine kinase inhibitor with antineoplastic potential. It appears to be the INN for Eilean Therapeutics' pan-FLT3/IRAK4 inhibitor (ZE46-0134) that is designed to simultaneously target clinically relevant resistance and activating FLT3 mutations and putative escape pathways (that arise via activation of IRAK4) in advanced AML [1].
|
|
References |
1. Byrd JC, Burd A, Ledwith BL, Pickersgill F, Dokukina K, Karapetian R, Johnstone ME, Hertlein EK, Elgamal OA, Pushechnikov A et al.. (2024)
A Randomized Placebo-Controlled Phase 1 Trial in Healthy Volunteers Investigating the Safety, Pharmacokinetics and Pharmacodynamics of a Novel FLT3/IRAK4 Inhibitor, Lomonitinib (ZE46-0134). Blood, 144 (Supplenent 1): 1396. DOI: 10.1182/blood-2024-211491 |